Pentraxin-3 in COPD: Innocent bystander or amplifier?

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 795-796

  Mantovani, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PENTRAXIN 3;

CANCER RISK; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; EDITORIAL; FORCED EXPIRATORY VOLUME; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMORAL IMMUNITY; MALIGNANT TRANSFORMATION; NONHUMAN; PENTRAXIN 3 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS;

C-REACTIVE PROTEIN; FEMALE; HUMANS; LUNG; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SERUM AMYLOID P-COMPONENT;

EID: 84860341614     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00198111     Document Type: Editorial

References (17)

1. Van Pottelberge GR, Bracke KR, Pauwels NS, et al. COPD is associated with reduced pulmonary interstitial expression of pentraxin-3. Eur Respir J 2012; 39: 830-838.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
3. Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28: 157-183.
4. Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008; 28: 1-13.
5. Kaess BM, Vasan RS. Heart failure: pentraxin 3 - a marker of diastolic dysfunction and HF? Nat Rev Cardiol 2011; 8: 246-248.
6. Meier P. Plasma sTWEAK and PTX3: new determinant tools of cardiovascular outcome also in patients with CKD. Clin J Am Soc Nephrol 2011; 6: 697-699.
7. VänskäM, Koivula I, Hämäläinen S, et al. High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica 2011; 96: 1385-1389.
8. Chiarini M, Sabelli C, Melotti P, et al. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 2011; 11: 665-670.
9. Mauri T, Masson S, Pradella A, et al. Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med 2010; 222: 105-112.
10. Mauri T, Coppadoro A, Bellani G, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008; 36: 2302-2308.
11. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-444.
12. Diamandis EP, Goodglick L, Planque C, et al. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 2011; 17: 2395-2399.
13. Pauwels NS, Bracke KR, Maes T, et al. Cigarette smoke induces PTX3 expression in pulmonary veins of mice in an IL-1 dependent manner. Respir Res 2011; 11: 134.
14. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11: 328-334.
15. Sica A, Mantovani A. Macrophages in polarized inflammation: in vivo veritas. J Clin Invest 2012; (in press).
16. May L, Kuningas M, van Bodegom D, et al. Genetic variation in pentraxin (PTX) 3 gene associates with PTX3 production and fertility in women. Biol Reprod 2010; 82: 299-304.
17. Olesen R, Wejse C, Velez DR, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun 2007; 8: 456-467. (Pubitemid 47370843)